Comparison · NCT00942877-sae
Adult Participants w/Alveolar Soft Part Sarcoma vs Pediatric Participants w/Alveolar Soft Part Sarcoma: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Adult Participants w/Alveolar Soft Part Sarcoma vs Pediatric Participants w/Alveolar Soft Part Sarcoma: serious adverse events. Trial comparisons, record NCT00942877-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00942877-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.478 | 0.341 | 0.619 | wilson | |
| Risk in group 2 | 0.857 | 0.487 | 0.974 | wilson | |
| Risk difference, group 1 minus group 2 | -0.379 | -0.559 | 0.0171 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.558 | 0.364 | 0.855 | log | |
| Odds ratio, group 1 over group 2 | 0.153 | 0.017 | 1.37 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Adult Participants w/Alveolar Soft Part Sarcoma than on Pediatric Participants w/Alveolar Soft Part Sarcoma | 2.64 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Adult Participants w/Alveolar Soft Part Sarcoma | Adult participants will be treated with 30 mg by mouth once a day for 28 days (28-day cycles).~AZD2171: Cediranib (AZD2171), a vascular endothelial growth factor (VEGF)/KIT tyrosine kinase inhibitor, has demonstrated antitumor activity in early phase clinical trials in adult and pediatric patients with Alveolar Soft Part Sarcoma (ASPS). | 22 | 46 | EG000 |
| Group 2 | Pediatric Participants w/Alveolar Soft Part Sarcoma | Pediatric participants (\<16 years old) will be treated with 12 mg/m\^2/day once a day for 28 days (28-day cycles).~AZD2171: Cediranib (AZD2171), a vascular endothelial growth factor (VEGF)/KIT tyrosine kinase inhibitor, has demonstrated antitumor activity in early phase clinical trials in adult and pediatric patients with Alveolar Soft Part Sarcoma (ASPS). | 6 | 7 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Participants were followed for the duration of treatment, an average of 16.9 cycles for adult patients and 34.7 cycles for pediatric patients (1 cycle = 28 days)
Source ClinicalTrials.gov
Trial
- Title
- Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma
- NCT number
- NCT00942877
- Phases
- PHASE2
- Conditions
- Sarcoma, Alveolar Soft Part
- Interventions
- AZD2171
- Lead sponsor
- National Cancer Institute (NCI)
- Results first posted
- 2021-04-27
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00942877?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00942877-sae